Sign in
4

Changes in Ownership

IRulya Therapeutics Inc. Filed Acc 0001209191-21-007540

Chief Executive Officer sold 60,000 shares at an average $38.49 ($2,309,600)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Lynch Casey Chief Executive Officer 2021-02-01 Sale −4,686 $34.60 $162,136 1,094,088 I: show line 1 in the form
Lynch Casey Chief Executive Officer 2021-02-01 Sale −3,100 $35.59 $110,329 1,090,988 I: show line 2 in the form
Lynch Casey Chief Executive Officer 2021-02-01 Sale −7,460 $36.56 $272,738 1,083,528 I: show line 3 in the form
Lynch Casey Chief Executive Officer 2021-02-01 Sale −4,283 $37.68 $161,383 1,079,245 I: show line 4 in the form
Lynch Casey Chief Executive Officer 2021-02-01 Sale −100 $38.28 $3,828 1,079,145 I: show line 5 in the form
Lynch Casey Chief Executive Officer 2021-02-01 Sale −371 $39.23 $14,554 1,078,774 I: show line 6 in the form
Lynch Casey Chief Executive Officer 2021-02-02 Sale −14,929 $36.02 $537,743 1,063,845 I: show line 7 in the form
Lynch Casey Chief Executive Officer 2021-02-02 Sale −5,071 $36.75 $186,359 1,058,774 I: show line 8 in the form
Open-market sales · 60,000 sh · avg $38.49 · $2,309,600
Loading xslF345X03/doc4.xml…